A View of TG Therapeutics Inc (TGTX) Stock’s Fundamentals and Valuations

TG Therapeutics Inc [TGTX] stock prices are up 4.12% to $13.91 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TGTX shares have gain 5.14% over the last week, with a monthly amount drifted -11.96%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

On 27, February 2024, TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy). In a post published today on Yahoo Finance, Newly issued patents extend exclusivity of ublituximab through 2042.

From an analyst’s perspective:

TG Therapeutics Inc [NASDAQ: TGTX] stock has seen the most recent analyst activity on August 02, 2023, when Goldman upgraded its rating to a Neutral and also revised its price target to $12 from $16. On May 20, 2022, BofA Securities initiated with a Underperform rating and assigned a price target of $5 on the stock. B. Riley Securities reiterated its Buy rating and decreased its price target to $35 on February 23, 2022. Goldman downgraded its rating to a Sell and reduced its price target to $26 on November 15, 2021. Goldman started tracking with a Neutral rating for this stock on April 20, 2021, and assigned it a price target of $50. In a note dated April 19, 2021, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $79 to $89.

The stock price of TG Therapeutics Inc [TGTX] has been fluctuating between $6.46 and $35.67 over the past year. Currently, Wall Street analysts expect the stock to reach $18.4 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $13.91 at the most recent close of the market. An investor can expect a potential return of 32.28% based on the average TGTX price forecast.

Analyzing the TGTX fundamentals

The TG Therapeutics Inc [NASDAQ:TGTX] reported sales of 189.77M for trailing twelve months, representing a surge of 176298.94%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.49 points at the first support level, and at 13.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.20, and for the 2nd resistance point, it is at 14.49.

TG Therapeutics Inc [TGTX] reported earnings per share of $0.73 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.12/share, meaning a difference of $0.61 and a surprise factor of 508.30%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.34 per share as compared to estimates of -$0.25 per share, a difference of -$0.09 representing a surprise of -36.00%.

Ratios To Look Out For

It’s worth pointing out that TG Therapeutics Inc [NASDAQ:TGTX]’s Current Ratio is 5.53. Also, the Quick Ratio is 4.95, while the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 11.10, the price to book ratio is 12.79.

Transactions by insiders

Recent insider trading involved Charney Laurence N, Director, that happened on Jan 05 when 17500.0 shares were sold. CFO, Power Sean A completed a deal on Jan 03 to sell 47867.0 shares. Meanwhile, CEO and President WEISS MICHAEL S bought 100000.0 shares on Aug 11.

Related Posts